Covid-19 Research

Case Report

Cis-platin Plus Paclitaxel Treatment in Cervical Carcinoma induce Hyperthyroidism: A Case Report

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Case Report
Subject Medicine Group
OCLC JBRES Record
Ashanjiang Aniwan*, Jian Mei, Xiaoye Deng, Guangli Ding, Hongli Zhou and Bichao Yu
Issue: Volume6-Issue10
Pages: 1440-1443
Received: 2025-10-01
Accepted: 2025-10-12
Published: 2025-10-15

Abstract

A patient in their 70s with cervical carcinoma developed hyperthyroidism after receiving treatment with cisplatin and paclitaxel. Laboratory tests confirmed the patient’s hyperthyroid status. Following the administration of anti-thyroid medications and the completion of the chemotherapy regimen, the patient’s thyroid function tended to stabilize. This case is infrequent, as few prior associations have been reported between these specific chemotherapeutic agents (cisplatin and paclitaxel) and hyperthyroidism. It thus suggests the existence of potential pathophysiological mechanisms underlying this phenomenon, underscoring the necessity of conducting further in-depth investigations. It also serves as a reminder to clinical practitioners that when encountering patients receiving chemotherapy who present with such symptoms, clinicians should consider hyperthyroidism in the differential diagnosis.

FullText HTML FullText PDF DOI: 10.37871/jbres2200 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2025 Aniwan A, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Aniwan A, Mei J, Deng X, Ding G, Zhou H, Yu B. Cis-platin Plus Paclitaxel Treatment in Cervical Carcinoma induce Hyperthyroidism: A Case Report. J Biomed Res Environ Sci. 2025 Oct 15; 6(10): 1440-1443. doi: 10.37871/jbres2200, Article ID: JBRES2200, Available at: https://www.jelsciences.com/articles/jbres2200.pdf

Subject area(s)

OncologyCancerClinical Endocrinology

References

  1. Elbe H. Once upon a time in Anatolia: the kings with bulging eyes. Hormones (Athens). 2024 Dec;23(4):841-847. doi: 10.1007/s42000-024-00561-y. Epub 2024 Apr 18. PMID: 38632215.
  2. Nasioudis D, Pashankar FD. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. Int J Gynecol Cancer. 2024 Sep 2;34(9):1454-1460. doi: 10.1136/ijgc-2023-005052. PMID: 38991656.
  3. Yang ST, Wang PH, Liu HH, Chang CW, Chang WH, Lee WL. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I). Taiwan J Obstet Gynecol. 2024 Sep;63(5):637-650. doi: 10.1016/j.tjog.2024.08.001. PMID: 39266144.
  4. Elmorsy EA, Saber S, Hamad RS, Abdel-Reheim MA, El-Kott AF, AlShehri MA, Morsy K, Salama SA, Youssef ME. Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies. Eur J Pharm Sci. 2024 Dec 1;203:106939. doi: 10.1016/j.ejps.2024.106939. Epub 2024 Oct 17. PMID: 39423903.
  5. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Paclitaxel. 2024 Jan 15. PMID: 29999636.
  6. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. doi: 10.1093/jnci/djr373. Epub 2011 Oct 18. PMID: 22010182; PMCID: PMC3206040.
  7. Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, Ibrayeva M, Sönmez Gürer E, Calina D, Hano C, Sharifi-Rad J. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023 May 9;14:1157306. doi: 10.3389/fphar.2023.1157306. PMID: 37229270; PMCID: PMC10203197.
  8. Adhikari S, Nath P, Das A, Datta A, Baildya N, Duttaroy AK, Pathak S. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies. Biomed Pharmacother. 2024 Feb;171:116211. doi: 10.1016/j.biopha.2024.116211. Epub 2024 Jan 29. PMID: 38290253.
  9. Zraik IM, Heß-Busch Y. Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen [Management of chemotherapy side effects and their long-term sequelae]. Urologe A. 2021 Jul;60(7):862-871. German. doi: 10.1007/s00120-021-01569-7. Epub 2021 Jun 29. PMID: 34185118.
  10. Hansen JF, Magyari M, Rasmussen Ã…K, Sellebjerg F, Feldt-Rasmussen U. Alemtuzumab-induced thyroid disease: A Danish cohort study. Mult Scler Relat Disord. 2024 Nov;91:105880. doi: 10.1016/j.msard.2024.105880. Epub 2024 Sep 6. PMID: 39293122.
  11. Kumar L, Upadhyay A, Jayaraj AS. Chemotherapy and immune check point inhibitors in the management of cervical cancer. Curr Probl Cancer. 2022 Dec;46(6):100900. doi: 10.1016/j.currproblcancer.2022.100900. Epub 2022 Oct 11. PMID: 36265252.
  12. Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021 Sep 15;11(9):4092-4110. PMID: 34659878; PMCID: PMC8493384.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership